The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeted combination therapy with fulvestrant (FUL) for second-line (2L) treatment of hormone receptor-positive (HR+) advanced breast cancer (ABC).
 
Ingrid A. Mayer
Consulting or Advisory Role - AstraZeneca; Novartis
Research Funding - Novartis; Pfizer
 
Ruth O'Regan
Honoraria - Genomic Health; Roche
Consulting or Advisory Role - Eisai; Genentech; Lilly; Pfizer; Puma Biotechnology
Travel, Accommodations, Expenses - BIND Biosciences; Celgene; Genentech; Genomic Health; Lilly; Novartis; Roche
 
Noah Saul Kornblum
No Relationships to Disclose
 
Kimberly L. Blackwell
Consulting or Advisory Role - Advaxis; Amgen; Amgen; Bayer; Celgene; Coherus Biosciences; Eisai; G1 Therapeutics; Genentech; Incyte; Lilly; Macrogenics; Merck; Novartis; Pfizer; Pierian Biosciences; Puma Biotechnology; Roche; Sandoz; Spectrum Pharmaceuticals
Research Funding - Genentech (Inst); Novartis (Inst); pfizer (Inst)
Travel, Accommodations, Expenses - Advaxis; Amgen; Celgene; Coherus Biosciences; Eisai; Genentech; Lilly; Macrogenics; Merck; Novartis; Pfizer; Pierian Biosciences; Puma Biotechnology; Roche; Sandoz